Nefecon: Completed Phase IIb enrollment

Pharmalink completed enrollment of 90 patients with primary IgA nephropathy in the double-blind, placebo-controlled, pivotal, European Phase IIb NEFIGAN trial evaluating 8 and 16 mg Nefecon daily for...